“New Strategies in Treating Respiratory Failure: NIV and HFNO as Complementary Therapies”
Event Navigation
Philips* & Saxe Communications present…”New Strategies in Treating Respiratory Failure: NIV and HFNO as Complementary Therapies”
Noninvasive ventilation (NIV) benefits have become increasingly recognized, in particular, NIV has proven effective for hypercapnic respiratory failure. High-flow nasal cannula (HFNO) has shown promise in treating hypoxic respiratory failure. This presentation will discuss how HFNO with NIV enables a complementary approach for weaning efficiency. In light of the current pandemic, this presentation will also discuss the use of HFNC and NIV therapy in COVID-19 patients. Following the lecture with be an interactive panel discussion with three experts in HFNO and NOV therapies.
Learning Objectives | After this activity, the participant will be able to:
- Discuss indications for NIV and HFNO
- Discuss the use of HFNC and NIV therapy in COVID-19 patients
- Demonstrate how HFNO and NIV can work in complementary fashion
Presenters:
Nicholas S. Hill, M.D. | Chief, Pulmonary & Critical Care and Sleep Division Pulmonary, Critical Care & Sleep Division | Tufts Medical Center | Boston, MA
Javier Belda, M.D., Ph.D. | Professor of Anesthesiology & Critical Care, Department of Surgery | Faculty of Medicine & Odontology | University of Valencia, Spain
Thomas Piraino, RRT, FCSRT, FAARC | Clinical Specialist | Centre of Excellence in Mechanical Ventilation | St. Michael’s Hospital | Toronto, Ontario
Continuing Education for Nurses and Respiratory Therapists.
This program has been approved for 1.0 contact hour. Continuing Respiratory Care Education (CRCE) credit by the American Association of Respiratory Care, 9425 N. MacArthur Blvd. Suite 100, Irving, TX 75063.
This education activity is approved for 1.0 contact hour. Provider approved by California Board of Nursing, Provider # 14477 and the Florida Board of Nursing Provider # 50-17032
Educational support provided by Philips*.
Questions should be directed to Saxe Communications: webinair@saxecommunications.com
* NOTE: This is a supplier and/or industry resource-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach.
